found that in hospitalized patients with COVID-19, platelet activation markers (such as thromboxane B2 (TXB2), p-selectin, and sCD40L) were associated with increased mortality, with plasma TXB2 increasing the risk of thrombosis (Figure 1A) (49). The gene discussed is CD40LG; the disease is COVID-19.